Trading Report: The Core Laboratories NV (CLB) to Issue Quarterly Dividend of $0.55 on November 22nd

The Core Laboratories NV (CLB) to Issue Quarterly Dividend of $0.55 on  November 22nd

Core Laboratories NV (NYSE:CLB) declared a quarterly dividend on Tuesday, October 11th. Stockholders of record on Friday, October 21st will be given a dividend of 0.55 per share on Tuesday, November 22nd. This represents a $2.20 dividend on an annualized basis and a dividend yield of 1.99%. The ex-dividend date of this dividend is Wednesday, October 19th.

Core Laboratories NV (NYSE:CLB) opened at 110.59 on Tuesday. Core Laboratories NV has a 12-month low of $84.50 and a 12-month high of $135.49. The stock has a market capitalization of $4.88 billion, a PE ratio of 58.67 and a beta of 1.45. The stock has a 50 day moving average price of $110.44 and a 200-day moving average price of $117.52.

A number of brokerages recently commented on CLB. Zacks Investment Research raised Core Laboratories NV from a “hold” rating to a “buy” rating and set a $138.00 target price on the stock in a report on Wednesday, July 20th. JPMorgan Chase & Co. reaffirmed a “buy” rating on shares of Core Laboratories NV in a report on Thursday, June 30th. Citigroup Inc. decreased their target price on Core Laboratories NV from $123.00 to $118.00 and set a “neutral” rating on the stock in a report on Monday, July 25th. DA Davidson began coverage on Core Laboratories NV in a report on Wednesday, October 5th. They issued a “buy” rating and a $136.00 target price on the stock. Finally, Credit Suisse Group AG began coverage on Core Laboratories NV in a report on Thursday, September 1st. They issued a “neutral” rating and a $115.00 target price on the stock. Three research analysts have rated the stock with a sell rating, eleven have assigned a hold rating and eight have given a buy rating to the stock. The company presently has a consensus rating of “Hold” and an average target price of $121.61.

A number of hedge funds have recently made changes to their positions in CLB. Parsons Capital Management Inc. RI increased its stake in shares of Core Laboratories NV by 3.6% in the second quarter. Parsons Capital Management Inc. RI now owns 2,150 shares of the company’s stock valued at $266,000 after buying an additional 75 shares during the last quarter. Fifth Third Bancorp increased its stake in shares of Core Laboratories NV by 15.3% in the second quarter. Fifth Third Bancorp now owns 1,166 shares of the company’s stock valued at $144,000 after buying an additional 155 shares during the last quarter. Janney Montgomery Scott LLC purchased a new stake in shares of Core Laboratories NV during the second quarter valued at about $252,000. AXA increased its stake in shares of Core Laboratories NV by 94.2% in the second quarter. AXA now owns 1,400 shares of the company’s stock valued at $173,000 after buying an additional 679 shares during the last quarter. Finally, Alliancebernstein L.P. increased its stake in shares of Core Laboratories NV by 520.7% in the second quarter. Alliancebernstein L.P. now owns 15,766 shares of the company’s stock valued at $1,953,000 after buying an additional 13,226 shares during the last quarter.

About Core Laboratories NV

Related posts

Leave a Comment